ClinicalTrials.gg
Enrolling by invitationNCT07645144FES-SCIUpdated Jun 12, 2026

FES-assisted Gait Training for Incomplete Spinal Cord Injury

An interventional study of FES-assisted gait training in Incomplete Spinal Cord Injury (SCI) and SCI - Spinal Cord Injury, sponsored by Stichting Reade. Enrolling by invitation at 1 site in Netherlands. Open to participants aged 17 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Stichting Reade · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2026, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
17 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Spinal Cord Injuries with a site in Netherlands — 5 open to participants now, 6 under way, none of them phase 3. Spinal Cord Injuries · Netherlands.

Planned enrollment
6th of 18
30 · median 18
Started
2026
with 1 other
No phase
17 of 22
5 open now
Registered
22nd of 22
by date
Lead sponsor
3 of 22
Stichting Reade

Among the 22 studies in Spinal Cord Injuries with a site in Netherlands, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 with no phase, and was the 22nd registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

5 of the 22 studies in Spinal Cord Injuries with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 17 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Spinal Cord Injuries with a site in Netherlands, or all of them as a file.
02

Study summary

Spinal cord injuries (SCI) impair neural communication, leading to difficulties in walking due to muscle weakness, altered reflexes, and impaired muscle activation below the injury. Functional electrical stimulation (FES) has been shown to enhance voluntary control, strength, and walking performance when used during gait training. This study aims to assess whether the FES yields superior improvements in walking ability compared to conventional gait training without stimulation.

Read the detailed description

Background:

Spinal cord injury (SCI) disrupts neural communication, resulting in impaired walking ability due to muscle weakness, altered reflex modulation, and reduced voluntary muscle activation below the lesion level. Functional electrical stimulation (FES) applied during gait training has been shown to enhance muscle activation and improve gait performance. However, it remains unclear whether gait training with automated multi-channel FES provides additional benefits beyond conventional treadmill gait training in individuals with chronic incomplete SCI (iSCI).

Objectives:

(1) To determine whether gait training combined with FES leads to greater improvements in overground walking speed compared to improvements observed during the preceding period of conventional gait training alone. (2) To evaluate retention of walking improvements following the FES intervention. (3) To explore whether changes in gait performance are associated with changes in muscle coordination and muscle strength.

Methods:

This study is a prospective single-group, repeated-measures study with two sequential intervention phases: 10 weeks of conventional treadmill gait training followed by 10 weeks of gait training with FES. Individuals with chronic iSCI (≥12 months post-injury; AIS C or D; neurological level C2-T12) will participate in a 23-week program. Assessments will be performed at baseline (T0), after conventional training (T1), after FES gait training (T2), and at 10-weeks post intervention (T3). The primary outcome is the 10-Meter Walk Test (10MWT) walking speed (m/s). The primary analysis compares the change in 10MWT performance during the FES-assisted phase (T2-T1) with the change during the conventional phase (T1-T0). Secondary outcomes include spatiotemporal gait parameters, Walking Index for Spinal Cord Injury II, Hoffer classification, treadmill gait performance, muscle activity, and isometric leg muscle strength.

03

Conditions studied

  • Incomplete Spinal Cord Injury (SCI)
  • SCI - Spinal Cord Injury
04

Who can participate

Ages eligible
17 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a non-progressive chronic (>1 yrs) incomplete SCI between C4 and T12 with an ASIA score of C or D.
  • Be at least 18 years of age.
  • Be able to take some steps (with assistive devices or in the bridge).
  • As part of the inclusion process, responsiveness to electrical stimulation will be assessed using a Compex electrical stimulator (Compex SP 4.0; Compex Medical SA, Switzerland) to ensure potential participant's respond well to ES, and to ensure that the sensitivity threshold is not reached before motor response in all target muscles.

Exclusion criteria

Exclusion Criteria:

  • Flaccid paralysis.
  • Musculoskeletal dysfunction, uncured fractures, contractures, pressure injuries, or infections that could impede the intended training.
  • Botox injections in the lower extremities during the last six months.
  • Women who are (planning to get) pregnant during the study period.
  • Implanted neurostimulator or stimulator of any kind that can have an influence on the safe use of ES.
  • Pacemaker, or other device, present in the body that prevents the safe use of ES.
  • Inability to communicate well or have cognitive disorders.
  • Currently being enrolled in another training study or participated in a training study in the previous six months.
  • Having an illness that has a high chance of preventing them to be able to perform the training at a sufficient frequency.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Conventional gait training

    Conventional gait training serves as the comparator condition and is performed without FES. Training is performed on a motorized treadmill, twice per week. Participants are secured in a safety harness system to prevent falls. Body-weight support may be provided with the minimum level of support determined during the first session and kept constant throughout the training period. Participants hold the treadmill handrails for balance support but are instructed not to use them for weight bearing. The initial treadmill speed is set to match the comfortable walking speed recorded during the baseline 10MWT. Speed may be adjusted during training according to the participants' walking capacity and safety considerations. If a participant is unable to complete the 10MWT, an appropriate starting speed will be estimated by the supervising physiotherapist/researcher.

    Other: FES-assisted gait training

Interventions

  • OtherFES-assisted gait training

    Following completion of the conventional training phase, participants continue with 20 sessions of gait training combined with FES. Training frequency, duration, and treadmill procedures remain identical to the conventional training phase, including the use of the safety harness system and the option for seated breaks during walking. During sessions, participants wear the trousers part of a full-body garment (Teslasuit, Deep Divers, London, UK), which delivers FES through integrated textile electrodes positioned over the target muscle groups.

06

What researchers measure

Primary outcomes

  1. walking speed

    The primary outcome is walking speed (m/s) on the 10MWT, assessed at T0, T1, T2, and T3. The primary analysis compares the change during the FES-assisted phase (T2-T1) with the change during the conventional phase (T1-T0). If a participant cannot complete the full 10 meters, the trial is excluded from the primary analysis and recorded as missing data

    Time frame: From enrollment to the end of study at 33 weeks

Secondary outcomes

  1. Spatiotemporal gait parameters - step length

    Step length (cm) will be assessed during the 10MWT using a markerless 3D full-body motion registration system (the Interactive Walkway; four Microsoft Kinect v2 sensors, 30Hz; Geerse et al., 2015). The gait parameters will be determined between the 2 and 8-meter line on the walkway to reduce the effect of gait acceleration and deceleration.

    Time frame: From enrollment to the end of study at 33 weeks

  2. Spatiotemporal gait parameters - step width

    Step width (cm) will be assessed during the 10MWT using a markerless 3D full-body motion registration system (the Interactive Walkway; four Microsoft Kinect v2 sensors, 30Hz; Geerse et al., 2015). The gait parameters will be determined between the 2 and 8-meter line on the walkway to reduce the effect of gait acceleration and deceleration.

    Time frame: From enrollment to the end of study at 33 weeks

  3. Spatiotemporal gait parameters - Cadence

    Cadence (steps/min) will be assessed during the 10MWT using a markerless 3D full-body motion registration system (the Interactive Walkway; four Microsoft Kinect v2 sensors, 30Hz; Geerse et al., 2015). The gait parameters will be determined between the 2 and 8-meter line on the walkway to reduce the effect of gait acceleration and deceleration.

    Time frame: From enrollment to the end of study at 33 weeks

  4. Functional ambulation - WISCI II

    Evaluated at T0, T1, T2, and T3 using the WISCI II (0-20).

    Time frame: From enrollment to the end of study at 33 weeks

  5. Functional ambulation - Hoffer classification

    Evaluated at T0, T1, T2, and T3 using the Hoffer classification (5-point scale).

    Time frame: From enrollment to the end of study at 33 weeks

  6. Muscle activity and neuromuscular coordination - Center of Activity

    Surface EMG (Trigno Wireless EMG System, Delsys Inc., Natick, USA) will be used to record muscle activity from eight muscles bilaterally during the 10MWTs. The muscle set comprises bilateral tibialis anterior (TA), gastrocnemius medialis (GAM), soleus (SOL), peroneus longus (PL), rectus femoris (RF), vastus lateralis (VL), gluteus maximus (GLM), and semitendinosus (ST). This selection provides a comprehensive overview of lower-limb muscle activity and is consistent with standard practices in gait research and clinical motor control studies (Agostini et al., 2020; Kotov-Smolenskiy et al., 2021). Center of Activity will be calculated for each muscle at T0, T1 and T2.

    Time frame: From enrollment to the end of study at 33 weeks

  7. Muscle activity and neuromuscular coordination - full width at half maximum

    Surface EMG (Trigno Wireless EMG System, Delsys Inc., Natick, USA) will be used to record muscle activity from eight muscles bilaterally during the 10MWTs. The muscle set comprises bilateral tibialis anterior (TA), gastrocnemius medialis (GAM), soleus (SOL), peroneus longus (PL), rectus femoris (RF), vastus lateralis (VL), gluteus maximus (GLM), and semitendinosus (ST). This selection provides a comprehensive overview of lower-limb muscle activity and is consistent with standard practices in gait research and clinical motor control studies (Agostini et al., 2020; Kotov-Smolenskiy et al., 2021). The full width at half maximum (FWHM) will be calculated at T0, T1 and T2.

    Time frame: From enrollment to the end of study at 33 weeks

  8. Muscle activity and neuromuscular coordination - Co-contraction

    Surface EMG (Trigno Wireless EMG System, Delsys Inc., Natick, USA) will be used to record muscle activity from eight muscles bilaterally during the 10MWTs. The muscle set comprises bilateral tibialis anterior (TA), gastrocnemius medialis (GAM), soleus (SOL), peroneus longus (PL), rectus femoris (RF), vastus lateralis (VL), gluteus maximus (GLM), and semitendinosus (ST). This selection provides a comprehensive overview of lower-limb muscle activity and is consistent with standard practices in gait research and clinical motor control studies (Agostini et al., 2020; Kotov-Smolenskiy et al., 2021). The Co-contraction will be calculated at T0, T1 and T2.

    Time frame: From enrollment to the end of study at 33 weeks

  9. Muscle strength

    Peak isometric knee extension and flexion torque (Nm) are assessed bilaterally using a load cell, with participants seated at 90° hip and knee flexion. Participants exert force against a fixed horizontal strap attached to a wall, with the force measured using the load cell. The lower leg is positioned perpendicular to the strap such that joint torque can be computed as load cell force × moment arm, where the moment arm (distance from the knee joint center to the strap attachment point on the lower leg) is measured at each trial. Three maximal trials per direction are performed; the highest value is the primary outcome and the mean of three trials is reported as a secondary consistency measure.

    Time frame: From enrollment to the end of study at 33 weeks

  10. Treadmill walking performance - Distance Covered

    Treadmill walking performance is monitored across all 40 training sessions. Distance covered (m) is recorded by the treadmill software at the end of each session.

    Time frame: During the 20 weeks training sessions

  11. Treadmill walking performance - Walking Speed

    Treadmill walking performance is monitored across all 40 training sessions. Walking speed (km/h) is recorded by the treadmill software at the end of each session.

    Time frame: During the 20 weeks training sessions

  12. Treadmill walking performance - Duration

    Treadmill walking performance is monitored across all 40 training sessions. Duration (min) is recorded by the treadmill software at the end of each session.

    Time frame: During the 20 weeks training sessions

  13. Gait kinematics during FES-assisted gait training

    Ankle and knee joint angles are recorded continuously across all 20 FES-assisted sessions using the six lower-body IMUs of the Teslasuit (femur, tibia, and foot bilaterally; 100 Hz). Raw data are stored for offline processing; all kinematic analyses are exploratory.

    Time frame: During the 10 week gait training with FES

07

Study locations

1 site
  • Stichting Reade
    Amsterdam, 1054HW, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 13 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 12, 2026
StartActual
Feb 9, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07645144
Lead sponsor
Stichting Reade
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Feb 9, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jun 12, 2026

Study contacts

Thomas Janssen, Prof. Dr.
principal investigator · Vrije Universiteit Amsterdam / Stichting Reade

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion